Although some genetic mutations are associated with high risk of relapse (CSF3R, WT1, and TET2; high-risk factors) in AML with CEBPAdm, the total frequency of those mutations is higher than the recurrence rate of CEBPAdm patients consolidated with auto-HSCT, which indicates that patients with those high-risk factors may also benefit from auto-HSCT. Here, WT1 is linked to acute myeloid leukemia.